|Bid||12.81 x 800|
|Ask||12.83 x 800|
|Day's Range||12.61 - 13.04|
|52 Week Range||9.74 - 27.82|
|Beta (5Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.38|
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; and Paolo Tombesi, Chief Financial Officer. Dr. Shefali Agarwal, Chief Medical Officer will join us for the Q&A session.
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?